


Listing of Claims

The following listing of claims replaces all prior listings of claims in this application:

1. (currently amended) A method for treating a condition selected from the group consisting of skin requiring desquamation, nail disorders, ~~dandruff~~, calluses, acne, ~~excess sebum production, and~~ enlarged skin pore size, ~~and blackheads~~ comprising contacting an area of affected skin with a composition having an effective amount of a halosalicylic acid compound of formula I,



wherein X is hydrogen or a cosmetically acceptable cation; R is hydrogen, C₁-C₁₈ alkyl or C₁-C₁₈ alkyl substituted with at least one Cl, Br, F or I group; and Y₁ and Y₂ are, independently, hydrogen, Cl, Br, F, I, methyl substituted by one to three Cl, Br, F, or I groups, phenyl, or phenyl substituted by at least one substituent selected from the group consisting of C₁-C₁₈ alkyl, Cl, Br, F and I; with the proviso that at least one of Y₁ and Y₂ is Cl, Br, F or I; and a cosmetically acceptable vehicle for the halosalicylic acid compound.

2. (currently amended) The method as claimed in according to claim 1, wherein the composition contains the halosalicylic acid compound in an amount of about 0.001% to about 10% by weight, based on total weight of the composition.
3. (currently amended) The method as claimed in according to claim 1, wherein the composition contains the halosalicylic acid compound in an amount of about 0.01% to about 5% by weight, based on total weight of the composition.

4. (currently amended) The method ~~as claimed in~~ according to claim 1, wherein the composition contains the halosalicylic acid compound in an amount of about 0.1% to about 2.5% by weight, based on total weight of the composition.
5. (currently amended) The method ~~as claimed in~~ according to claim 1, wherein the composition contains the halosalicylic acid compound in an amount of about 0.25% ~~0.5%~~ to about 2% by weight, based on total weight of the composition.
6. (currently amended) The method ~~as claimed in~~ according to claim 1, wherein the compound of formula I is selected from the group consisting of 5-chlorosalicylic acid, 5-fluorosalicylic acid, 5-bromosalicylic acid, 5-iodosalicylic acid and mixtures thereof, or cosmetically acceptable salts thereof.
7. (currently amended) The method ~~as claimed in~~ according to claim 1, wherein the compound of formula I is 5-chlorosalicylic acid, or a cosmetically acceptable salt thereof.
8. (currently amended) The method ~~as claimed in~~ according to claim 1, wherein the composition further contains salicylic acid.
9. (currently amended) The method ~~as claimed in~~ according to claim 8, wherein the salicylic acid is present in an amount of ~~about 0.0625%~~ 0.5% to about 2% by weight, based on total weight of the composition, the halosalicylic acid compound is 5-chlorosalicylic acid, and the 5-chlorosalicylic acid is present in an amount of about 0.1% 0.5% to about 2% by weight, based on total weight of the composition.
10. (currently amended) The method ~~as claimed in~~ according to claim 1, wherein the composition further contains an RAR/RXR agonist.
11. (currently amended) The method ~~as claimed in~~ according to claim 1, wherein the composition further contains a 5-alpha-reductase inhibitor.

12. (currently amended) The method ~~as claimed in~~ according to claim 1, wherein the composition further contains an RAR/RXR agonist and a 5-alpha-reductase inhibitor.
13. (currently amended) The method ~~as claimed in~~ according to claim 10, wherein the RAR/RXR agonist is present in an amount of about 0.0001% to about 50% by weight, based on the total weight of the composition.
14. (currently amended) The method ~~as claimed in~~ according to claim 10, wherein the RAR/RXR agonist is present in an amount of about 0.01% to about 20% by weight, based on the total weight of the composition.
15. (currently amended) The method ~~as claimed in~~ according to claim 10, wherein the RAR/RXR agonist is present in an amount of about 0.5% to about 5% by weight, based on the total weight of the composition.
16. (currently amended) The method ~~as claimed in~~ according to claim 11, wherein the 5-alpha-reductase inhibitor is present in an amount of about 0.01% to about 5% by weight, based on the total weight of the composition.
17. (currently amended) The method ~~as claimed in~~ according to claim 11, wherein the 5-alpha-reductase inhibitor is present in an amount of about 0.1% to about 0.5% by weight, based on the total weight of the composition.
18. (currently amended) The method ~~as claimed in~~ according to claim 10, wherein the RAR/RXR agonist is selected from the group consisting of phytol, isophytol, phytol derivatives, isophytol derivatives, retinoids, and mixtures thereof.
19. (currently amended) The method ~~as claimed in~~ according to claim 10, wherein the RAR/RXR agonist is phytol, retinol or a mixture thereof.

20. (currently amended) The method as claimed in according to claim 11, wherein the 5-alpha-reductase inhibitor is selected from the group consisting of oleanolic acid, saw palmetto, finasteride, and mixtures thereof.

21. (currently amended) The method as claimed in according to claim 1, wherein the composition further contains an anti-ageing active ingredient.


22. (withdrawn) The method of claim 1, wherein the condition is skin requiring desquamation.

23. (original) The method of claim 1, wherein the condition is enlarged skin pore size.

24. (currently amended) The method of claim 11[.] according to claim 23, wherein the condition is excess sebum production compound of formula I is 5-chlorosalicylic acid, or a cosmetically acceptable salt thereof.

25. (currently amended) The method of claim 11[.] according to claim 24, wherein the condition is acne or blackheads composition further comprises an antioxidant.

26. (withdrawn) A cosmetic composition comprising an effective amount of a halosalicylic acid compound of formula I,



wherein X is hydrogen or a cosmetically acceptable cation; R is hydrogen, C₁-C₁₈ alkyl or C₁-C₁₈ alkyl substituted with at least one Cl, Br, F or I group; and Y₁ and Y₂ are, independently, hydrogen, Cl, Br, F, I, methyl substituted by one to three Cl, Br, F, or I groups, phenyl, or phenyl substituted by at least one substituent selected from the group consisting of C₁-C₁₈ alkyl, Cl, Br, F and I; with the proviso that at least one

of Y₁ and Y₂ is Cl, Br, F or I; and a cosmetically acceptable vehicle for the halosalicylic acid compound.

27. (new) A method for reducing the size of enlarged skin pores, comprising contacting an area of affected skin with a composition comprising an effective amount of 5-chlorosalicylic acid, or a cosmetically acceptable salt thereof, and a cosmetically acceptable vehicle.
28. (new) The method according to claim 27, wherein said 5-chlorosalicylic acid, or a cosmetically acceptable salt thereof, comprises from about 0.1% to about 2.5% by weight, based on total weight of the composition.
29. (new) The method according to claim 28, wherein said 5-chlorosalicylic acid, or a cosmetically acceptable salt thereof, comprises from about 0.25% to about 2% by weight, based on total weight of the composition.
30. (new) The method according to claim 28, wherein said composition further comprises a mattifying agent to minimize the color contrast between an enlarged pore and its surrounding skin.
31. (new) The method according to claim 30, wherein said mattifying agent comprises dimethicone.
32. (new) The method according to claim 28, wherein said composition further comprises an antioxidant.
33. (new) The method according to claim 32, wherein said antioxidant has one or more thiol functions, in either reduced or non-reduced form.
34. (new) The method according to claim 32, wherein the antioxidant is vitamin C.

35. (new) The method according to claim 28, wherein said composition further comprises one or more anti-aging actives.
36. (new) The method according to claim 35, wherein the anti-ageing active is an alpha hydroxy acid.
37. (new) The method according to claim 28, wherein the further comprises lactic acid, glycolic acid, or a combination thereof.
38. (new) The method according to claim 28, wherein the composition further comprises an exfoliant selected from the group consisting of alpha hydroxy acids, beta hydroxy acids, keto acids, oxa acid, oxa diacid, and mixtures thereof.
39. (new) The method according to claim 38, wherein the oxa acid is trioxundecanedioic acid.
40. (new) The method according to claim 28 further comprising ascorbyl-phospheryl-cholesterol.
41. (new) The method according to claim 28, wherein said composition further comprises a retinoid.